Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event

Core Insights - Acrivon Therapeutics presents initial positive clinical data from the Phase 2 ACR-368 trial, showing a 50% confirmed overall response rate in OncoSignature-positive patients with ovarian and endometrial cancers [1][3] - The AP3 patient selection platform has demonstrated its ability to predict responders to ACR-368 treatment, with a statistically significant p-value of 0.0038 [1][3] - ACR-2316, a potential first-in-class dual WEE1/PKMYT1 inhibitor, has an accelerated IND filing timeline now expected in Q3 2024 [1][4] Clinical Data Highlights - Initial clinical data from the ongoing Phase 2b trial includes 26 patients, with 10 OncoSignature-positive and 16 OncoSignature-negative [1][3] - A confirmed overall response rate of 50% was observed in OncoSignature-positive patients, while no responders were found in the OncoSignature-negative group [3][4] - The median duration of response has not yet been reached, and all confirmed responders continue treatment [3] AP3 Platform Validation - The ACR-368 OncoSignature assay has shown prospective validation in identifying patients likely to respond to ACR-368 monotherapy [2][3] - The assay effectively segregated RECIST responders, confirming a 50% overall response rate in OncoSignature-positive patients compared to 0% in OncoSignature-negative patients [3] ACR-2316 Development - ACR-2316 is designed for superior single-agent activity and is advancing rapidly, with IND filing now expected in Q3 2024 and clinical trial initiation anticipated in Q4 2024 [1][4] - The compound aims to address significant unmet treatment needs across a broad range of tumors [2][4] Event and Presentation - Acrivon hosted a corporate R&D event to present these findings, with a live and recorded webcast available for investors [5]